ン3. コ1. コ2

Express Mail No.: EL 477 034 4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

Application of: Kensil, Charlotte

MAR - 8 2002

Application No.: 09/760,506

Art Unit: 1636

Filed: January 12, 2001

Examiner: Sita S. Pappu

TECH CENTER 1600/2900

INNATE IMMUNITY-STIMULATING

Atty Docket No.:8449-153-999

COMPOSITIONS OF CPG AND SAPONIN AND

New York, NY

METHODS THEREOF

February 26, 2002

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.111

COPY OF PAPERS ORIGINALLY FILED

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

FEB 2 6 2002

In response to the communication from the Examiner and a Notice to Comply with Requirements for Patent Applications mailed February 8, 2002, Applicant submits herewith the following amendments and the remarks below. Accompanying this Preliminary Amendment is: 1) Exhibit A, a marked-up version of the replacement paragraphs of the specification; 2) Exhibit B, a marked-up version of the amended claims; 3) Exhibit C, a list of pending claims upon entry of the present amendments; 4) a Transmittal of Sequence Listing with a Sequence Listing in paper and computer-readable format; and 5) a copy of the Notice to Comply with Requirements for Patent Application.

IN THE SPECIFICATION:

A marked-up version of the following amended paragraphs are attached as Exhibit A. Please amend the Specification as follows:

On pages 4 and 5, please replace the paragraph beginning, "Accordingly, in a first aspect" with the following paragraph:

--Accordingly, in a first aspect, the invention covers a composition comprising: (a) a saponin; and (b) an oligonucleotide comprising at least one unmethylated CpG dinucleotide. Preferably, the composition provides that the saponin is derived from Quillaja saponaria, and more preferably, the saponin is chemically modified or comprises a substantially pure saponin. In a preferred embodiment of the first aspect, the substantially pure saponin comprises QS-7, QS-17,

NY2 - 1290611.1